{"id":5956,"date":"2023-07-18T07:30:27","date_gmt":"2023-07-18T11:30:27","guid":{"rendered":"https:\/\/bridgebio.local\/news\/auto-draft\/"},"modified":"2023-07-15T21:21:30","modified_gmt":"2023-07-16T01:21:30","slug":"bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-28","status":"publish","type":"post","link":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-28\/","title":{"rendered":"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"<p align=\"left\"><strong>PALO ALTO, Calif., July 18, 2023 (GLOBE NEWSWIRE)<\/strong> &#8212; BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on July 10, 2023, the compensation committee of BridgeBio\u2019s board of directors granted eight new employees restricted stock units for an aggregate of 71,250 shares of the Company\u2019s common stock. One-fourth of the shares underlying each employee\u2019s restricted stock units will vest on August 16, 2024, with one-twelfth of the remaining shares underlying each such employee\u2019s restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee\u2019s continued employment with the Company or one of its subsidiaries on such vesting dates. All of the above-described awards were made under BridgeBio\u2019s Amended and Restated 2019 Inducement Equity Plan (the &#8220;Plan&#8221;).<\/p>\n<p>The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio\u2019s board of directors in November 2019 and amended and restated on February 10, 2023.<\/p>\n<p><strong>About BridgeBio Pharma, Inc.<\/strong><br \/>\nBridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio\u2019s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit\u00a0<a href=\"http:\/\/www.bridgebio.local\/\" target=\"_blank\" rel=\"nofollow noopener\"><strong>bridgebiodev.wpengine.com<\/strong><\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.linkedin.com\/company\/bridgebio\/\" target=\"_blank\" rel=\"nofollow noopener\"><strong>LinkedIn<\/strong><\/a>\u00a0and\u00a0<a href=\"https:\/\/twitter.com\/BridgeBioPharma\" target=\"_blank\" rel=\"nofollow noopener\"><strong>Twitter<\/strong><\/a>.<\/p>\n<p><strong>BridgeBio Contact:<\/strong><br \/>\nVikram Bali<br \/>\n<a href=\"mailto:contact@bridgebiodev.wpengine.com\" target=\"_blank\" rel=\"nofollow noopener\">contact@bridgebiodev.wpengine.com<\/a><a href=\"mailto:contact@bridgebiodev.wpengine.com\" target=\"_blank\" rel=\"nofollow noopener\"><br \/>\n<\/a>(650)-789-8220<\/p>\n","protected":false},"excerpt":{"rendered":"<p>PALO ALTO, Calif., July 18, 2023 (GLOBE NEWSWIRE) &#8212; BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on July 10, 2023, the compensation committee of BridgeBio\u2019s board of directors granted eight new employees restricted stock units for an aggregate of 71,250 [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[8],"tags":[],"class_list":["post-5956","post","type-post","status-publish","format-standard","hentry","category-news"],"acf":{"people":false,"external_link":"","presentation":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - BridgeBio<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-28\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - BridgeBio\" \/>\n<meta property=\"og:description\" content=\"PALO ALTO, Calif., July 18, 2023 (GLOBE NEWSWIRE) &#8212; BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on July 10, 2023, the compensation committee of BridgeBio\u2019s board of directors granted eight new employees restricted stock units for an aggregate of 71,250 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-28\/\" \/>\n<meta property=\"og:site_name\" content=\"BridgeBio\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-18T11:30:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-16T01:21:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Holly Condon\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@BridgeBioPharma\" \/>\n<meta name=\"twitter:site\" content=\"@BridgeBioPharma\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Holly Condon\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-28\/\",\"url\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-28\/\",\"name\":\"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - BridgeBio\",\"isPartOf\":{\"@id\":\"https:\/\/bridgebio.com\/#website\"},\"datePublished\":\"2023-07-18T11:30:27+00:00\",\"dateModified\":\"2023-07-16T01:21:30+00:00\",\"author\":{\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/e56e9128cd840531b0acdca992cb1fca\"},\"breadcrumb\":{\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-28\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-28\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-28\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bridgebio.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/bridgebio.com\/#website\",\"url\":\"https:\/\/bridgebio.com\/\",\"name\":\"BridgeBio\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/bridgebio.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/e56e9128cd840531b0acdca992cb1fca\",\"name\":\"Holly Condon\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/4465d7631588f41599cacc7a8380e613?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/4465d7631588f41599cacc7a8380e613?s=96&d=mm&r=g\",\"caption\":\"Holly Condon\"},\"url\":\"https:\/\/bridgebio.com\/author\/hcondon\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - BridgeBio","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-28\/","og_locale":"en_US","og_type":"article","og_title":"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - BridgeBio","og_description":"PALO ALTO, Calif., July 18, 2023 (GLOBE NEWSWIRE) &#8212; BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on July 10, 2023, the compensation committee of BridgeBio\u2019s board of directors granted eight new employees restricted stock units for an aggregate of 71,250 [&hellip;]","og_url":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-28\/","og_site_name":"BridgeBio","article_published_time":"2023-07-18T11:30:27+00:00","article_modified_time":"2023-07-16T01:21:30+00:00","og_image":[{"width":1200,"height":600,"url":"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png","type":"image\/png"}],"author":"Holly Condon","twitter_card":"summary_large_image","twitter_creator":"@BridgeBioPharma","twitter_site":"@BridgeBioPharma","twitter_misc":{"Written by":"Holly Condon","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-28\/","url":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-28\/","name":"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - BridgeBio","isPartOf":{"@id":"https:\/\/bridgebio.com\/#website"},"datePublished":"2023-07-18T11:30:27+00:00","dateModified":"2023-07-16T01:21:30+00:00","author":{"@id":"https:\/\/bridgebio.com\/#\/schema\/person\/e56e9128cd840531b0acdca992cb1fca"},"breadcrumb":{"@id":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-28\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-28\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-28\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bridgebio.com\/"},{"@type":"ListItem","position":2,"name":"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/bridgebio.com\/#website","url":"https:\/\/bridgebio.com\/","name":"BridgeBio","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bridgebio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/bridgebio.com\/#\/schema\/person\/e56e9128cd840531b0acdca992cb1fca","name":"Holly Condon","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/bridgebio.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/4465d7631588f41599cacc7a8380e613?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4465d7631588f41599cacc7a8380e613?s=96&d=mm&r=g","caption":"Holly Condon"},"url":"https:\/\/bridgebio.com\/author\/hcondon\/"}]}},"_links":{"self":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts\/5956"}],"collection":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/comments?post=5956"}],"version-history":[{"count":0,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts\/5956\/revisions"}],"wp:attachment":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/media?parent=5956"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/categories?post=5956"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/tags?post=5956"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}